AGE-RAGE in Multiple Sclerosis Brain

Abstract

This pilot study used immunohistochemical techniques to investigate the advanced glycation end-product (AGE) Nepsilon-(carboxymethyl)lysine (CML) and its receptor (RAGE) in the brains of multiple sclerosis (MS) patients, comparing them with the brains of patients with Alzheimer's disease (AD) (positive controls) and with age-matched control subjects (negative controls). Postmortem slides derived from the hippocampi of MS patients, AD patients, and controls were stained with monoclonal antibodies for CML and human RAGE. Results showed increased AGE and RAGE immunostaining in the hippocampi of MS patients, similar to AD patients.

Keywords:

• Advanced glycation end-products
• Alzheimer's disease
• Immunohistochemistry
• Multiple sclerosis
• RAGE

ACKNOWLEDGMENTS

The authors thank “Jog for the Jake” for support of the study and Ms. Joy Harrison for editorial excellence.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. There was no funding from any pharmaceutical or other company.